Xenon Halts Depression Trials Over Psychosis Reports, Files Epilepsy NDA

Key points

• Xenon paused new patient enrollment in X-Nova2 (major depressive disorder) and X-Ceed (bipolar depression) phase 3 trials due to reports of mild to moderate adverse events, including psychosis.
• The company continues to treat existing participants and has notified the FDA, planning to adjust dosing over the coming months to enhance tolerability.
• Xenon filed a New Drug Application for azetukalner in focal seizures, supported by over 1,500 patient-years of safety data from epilepsy trials.
• The X-Nova2 trial had enrolled approximately 360 participants, reaching 80% of its target, and the company plans to report topline data in the first quarter of 2027.
• Xenon’s stock fell 26% to $42.25 in pre-market trading following the announcement, reflecting investor concern over the depression program's viability.

Background

This development follows a period of heightened public scrutiny on mental health treatments, including high-profile cases like the Lindsay Clancy trial, which highlighted gaps in psychiatric care and medication management. Additionally, recent discussions on maternal mental health have emphasized the need for accessible and effective treatments for mood disorders. Xenon’s azetukalner, a Kv7 potassium channel opener, is being evaluated for both epilepsy and depression, with the epilepsy program showing a favorable risk-benefit profile despite isolated psychosis cases.

How outlets are covering it

Fierce Biotech reports that Xenon’s Chief Medical Officer, Christopher Kenney, described the adverse events as short in duration and reversible, with no long-term sequelae. He emphasized that the pause is temporary and that dosing adjustments will address tolerability issues. William Blair analysts agreed, noting that psychosis rates in azetukalner are comparable to those of blockbuster antidepressants like Zoloft and Wellbutrin. However, they lowered their probability of success for azetukalner in MDD from 60% to 50%, citing mixed phase 2 data. Yahoo Finance’s coverage, while largely obscured by technical errors, confirms the stock’s significant drop and the filing of the NDA for epilepsy, aligning with Fierce Biotech’s report on the dual-track strategy. Both sources agree that the Xenon pause is unrelated to Biohaven’s recent pause in a similar Kv7 activator trial, indicating no broader class safety concern.

Why it matters

The pause in Xenon’s depression trials highlights the ongoing challenges in developing new psychiatric medications, where balancing efficacy with safety remains a critical hurdle. The decision to proceed with the epilepsy NDA while adjusting the depression program demonstrates a strategic approach to mitigating risk. For investors and patients, this underscores the importance of rigorous safety monitoring in clinical trials and the potential for dosing adjustments to improve outcomes. The stock’s sharp decline reflects market sensitivity to adverse event reports, even when viewed as temporary by the company and analysts.

What to watch

Xenon plans to implement dosing adjustments over the coming months and will report topline data from the X-Nova2 trial in the first quarter of 2027. The company will continue treating existing participants in both depression and epilepsy trials. The FDA’s review of the NDA for focal seizures is expected to proceed, with the epilepsy program’s safety data providing a strong foundation for approval. Investors will closely monitor the impact of the dosing changes on tolerability and the eventual results from the depression trials.